batrachotoxinin A 20-alpha-benzoate

08/01/2003 - "Patients with MPS who received BTX-A reported significantly greater reductions in pain for longer durations compared with those who received BTX-B. "
08/01/2003 - "Patients who received BTX-A had significantly greater mean reductions in VAS pain scores compared with those who received BTX-B (mean reduction, 2.7 vs 1.8, respectively; P < 0.001). "
12/01/2001 - "In two large pivotal trials, BTX-B was found to be safe and effective in decreasing the movements, pain and disability associated with CD. "
09/01/2015 - "Two months after LSB with BTX-B, pain intensity and the Leeds assessment of neuropathic symptoms and signs (LANSS) score were significantly reduced. "
12/01/2014 - "Injection pain of BTX-B changed to pH 7.5 was significantly reduced and retained efficacy over 10 weeks. "

10/01/2014 - "In this prospective, uncontrolled study Btx B seems to be both a safe and effective treatment in craniofacial hyperhidrosis improving quality of life and reducing extreme sweating."
03/01/2005 - "There are sparse data, however, in the literature evaluating the safety and efficacy of BTX-B for the treatment of palmar hyperhidrosis. "
10/01/2014 - "To evaluate the safety and clinical effect of Btx B in craniofacial hyperhidrosis. "
01/01/2004 - "This chapter will review what is currently known about BTX-B and its current use in regards to the treatment of hyperhidrosis."
01/01/2004 - "This past year researchers have been investigating the efficacy as well as defining the dosing and application regiments of BTX-B in the treatment of hyperhidrosis. "

04/01/2003 - "BTX-B was approved for use in cervical dystonia in 2000, but it has been used off-label to treat facial wrinkles as reported in several open-label studies. "
01/01/2001 - "A study in patients who continued to respond to BTX-A and a similarly designed study in patients who were resistant to BTX-A demonstrated statistical improvement in the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) in those treated with BTX-B (evaluated as NeuroBloc) compared with placebo. "
07/01/2005 - "Botulinum toxin type B (BTX-B) has been approved by the Food and Drug Administration for the treatment of cervical dystonia. "
05/01/2005 - "Botulinum toxin type B (BTX-B, Myobloc, San Francisco, CA, USA) was FDA-approved for the treatment of cervical dystonia in December 2000. "
01/01/2004 - "Like botulinum toxin type A (BTX-A), BTX-B has been used for a myriad of both dermatologic and nondermatologic problems since its recent approval by the FDA for the treatment of cervical dystonia in December 2000. "

12/01/2005 - "Thirty-two patients with adductor spasmodic dysphonia with stable doses of A toxin to manage their symptom were given type B toxin starting at a conversion of 1 U of BTX-A to 50 U of BTX-B. "
06/01/2019 - "BTX-B injections into the PCA muscle also greatly improved his dysphonia. "
12/01/2005 - "This study shows that a conversion factor of 52.3:1 Myobloc (BTX-B) to Botox (BTX-A) and that Myobloc is an effective alternative to Botox (BTX-A) for patients with spasmodic dysphonia."

04/01/2012 - "Residual limb pain improved 3 months after intracutaneous, low-dose BTX-B in a trial with 9 patients and also phantom pain by tendency. "